At a glance
ClinicalIndex Comparison RecordPhase 3Active· 101 enrolled
Drug / intervention
Ixekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab and Adalimumab for Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis. Active but no longer recruiting, targeting 101 participants across 43 sites in 12 countries.
Detailed Summary
The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis \[JoAS\]) and juvenile psoriatic arthritis (JPsA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Belgium, Czechia, Denmark, France, Germany, Italy, Mexico, Netherlands, Spain, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 3Active
20212022202320242025202620272028
First PostedAug 2020
Enrollment StartApr 2021
Primary CompletionFeb 2024
TodayJul 2026
Study CompletionApr 2028
First PostedAug 26, 2020
Enrollment StartApr 13, 2021
Primary CompletionFeb 19, 2024
Study CompletionApr 1, 2028
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.9 years ago
Interventions
Ixekizumabdrug
Administered SC
Adalimumabdrug
Administered SC